TScan Therapeutics, Inc.

NGM: TCRX

Live Quote

📈 ZcoreAI Score

Our AI model analyzes TScan Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get TCRX Z-Score →

About TScan Therapeutics, Inc.

Healthcare Biotechnology

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

📊 Fundamental Analysis

TScan Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.

The company recently reported 286.0% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is -71.3%, which indicates that capital utilization is currently under pressure.

At a current price of $1.05, TCRX currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $0.88 - $2.57).

🏥 Financial Health

🔴 Profit Margin Weak

🔴 Debt/Equity Elevated

✅ Revenue Growth Excellent

🔴 Return on Equity Weak

⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap

$59.75M

Trailing P/E

Forward P/E

-1.37

Beta (5Y)

1.01

52W High

$2.57

52W Low

$0.88

Avg Volume

570K

Day High

Day Low

Get TCRX Z-Score on Dashboard 🚀